Reference number : GC-2017-Q4-01233, amendment number : , agreement type : G, recipient legal name : Melacini, Giuseppe (McMaster University), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Therapure Biopharma Inc. (or Therapure in short) already developed a highly competitive product, referred to_x000D_
here as "TBI-HSA", which is a therapeutic albumin designed for the cost-effective treatment of hypovolemia_x000D_
and the control of oncotic pressure in surgical applications. Therapeutic albumin is also undergoing phase III_x000D_
clinical trials based on its potential use for treating dementia in Alzheimer's patients. The TBI-HSA biologics_x000D_
is a viable alternative to traditional albumins obtained through Cohn's fractionation of pooled human plasma_x000D_
and the prospect of future growth is excellent due to the rapidly aging population of Canada and the projected_x000D_
increase in demand for plasma biologics during surgeries. In order to fully exploit the full potential of the_x000D_
technology developed by Therapure for growth in these markets, it is essential to understand at the molecular_x000D_
level how the manufacturing process of TBI-HSA affects the active ingredient of this formulation, i.e. the_x000D_
albumin protein. Here, we propose to determine through advanced Nuclear Magnetic Resonance (NMR)_x000D_
spectroscopy methods how a critical step of the TBI-HSA manufacturing process, the addition of stabilizers to_x000D_
enhance albumin stability, perturbs the interactions of albumin with common drugs, such as naproxen and_x000D_
warfarin. Considering that alteration in these interactions affects the ability of albumin to function as a_x000D_
biotherapeutic, the molecular images provided by NMR will inform the future optimization of the_x000D_
manufacturing process implemented by Therapure. This type of optimization will provide Therapure a unique_x000D_
competitive edge relative to its international competitors and thus will help Therapure significantly expand its_x000D_
worldwide market. However, Therapure currently has no access to the specialized NMR expertise required to_x000D_
gain this competitive edge. The Melacini group will provide the necessary expertise, as Dr. Melacini_x000D_
specializes in the biophysical characterization of proteins by NMR. The application of these NMR imaging_x000D_
methodologies to monitor how the TBI-HSA active ingredient changes during the manufacturing process will_x000D_
allow Therapure to further expand its share in the plasma biologics market., program purpose french : Therapure Biopharma Inc. (or Therapure in short) already developed a highly competitive product, referred to_x000D_
here as "TBI-HSA", which is a therapeutic albumin designed for the cost-effective treatment of hypovolemia_x000D_
and the control of oncotic pressure in surgical applications. Therapeutic albumin is also undergoing phase III_x000D_
clinical trials based on its potential use for treating dementia in Alzheimer's patients. The TBI-HSA biologics_x000D_
is a viable alternative to traditional albumins obtained through Cohn's fractionation of pooled human plasma_x000D_
and the prospect of future growth is excellent due to the rapidly aging population of Canada and the projected_x000D_
increase in demand for plasma biologics during surgeries. In order to fully exploit the full potential of the_x000D_
technology developed by Therapure for growth in these markets, it is essential to understand at the molecular_x000D_
level how the manufacturing process of TBI-HSA affects the active ingredient of this formulation, i.e. the_x000D_
albumin protein. Here, we propose to determine through advanced Nuclear Magnetic Resonance (NMR)_x000D_
spectroscopy methods how a critical step of the TBI-HSA manufacturing process, the addition of stabilizers to_x000D_
enhance albumin stability, perturbs the interactions of albumin with common drugs, such as naproxen and_x000D_
warfarin. Considering that alteration in these interactions affects the ability of albumin to function as a_x000D_
biotherapeutic, the molecular images provided by NMR will inform the future optimization of the_x000D_
manufacturing process implemented by Therapure. This type of optimization will provide Therapure a unique_x000D_
competitive edge relative to its international competitors and thus will help Therapure significantly expand its_x000D_
worldwide market. However, Therapure currently has no access to the specialized NMR expertise required to_x000D_
gain this competitive edge. The Melacini group will provide the necessary expertise, as Dr. Melacini_x000D_
specializes in the biophysical characterization of proteins by NMR. The application of these NMR imaging_x000D_
methodologies to monitor how the TBI-HSA active ingredient changes during the manufacturing process will_x000D_
allow Therapure to further expand its share in the plasma biologics market., agreement title english : Mapping the Effect of Excess Fatty Acids on Albumin-Drug Interactions by NMR, agreement title french : Mapping the Effect of Excess Fatty Acids on Albumin-Drug Interactions by NMR, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada